TD Cowen on Arrowhead Pharma (ARWR): 'We remain at Buy as the pipeline remains robust'

March 26, 2026 2:33 PM

TD Cowen analyst Joseph Thome reiterated a Buy rating on Arrowhead Pharma (NASDAQ: ARWR).The analyst comments "WVE released additional data ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found